Somebody else pays first: management describes counterparties putting their own money down ahead of delivery
The model's full reasoning — Q3 2016 call → NOWe need to determine if management describes counterparties putting their own money/resources at risk before receiving what they are paying for, as something happening now. The transcript is about MacroGenics, a biotech. They have collaborations, partnerships, etc. The question is about pre-funding by customers/partners. In the transcript, they mention revenues from collaborative agreements, milestones, etc. But do they describe partners paying upfront fees or committing capital in advance of delivery? They mention a one-time milestone from Janssen in 2015, but that's past. They also mention collaboration payments they anticipate receiving. But is there any description of counterparties currently committing money in advance? They talk about Takeda returning rights, etc. No explicit mention of deposits, prepayments, or partners funding development. They have grants from NIH/NIAID, but that's not commercial counterparties. They have collaborations with Merck, Janssen, Pfizer, but no mention of upfront payments or advance commitments. The question is about "people on the OTHER SIDE of the company's business" putting their own money at risk before receiving what they pay for. In biotech, partners often pay upfront fees for licenses, but here they don't mention that. They mention "collaboration payments we anticipate receiving" but that's future. They also mention "revenues consisting primarily of revenues from collaborative agreements" but that's standard. No specific description of advance commitments. So answer NO. Thus answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| BLZE | Backblaze, Inc. | Q3 2022 | 2022-11-11 | D |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| SRDX | Surmodics, Inc. | Q3 2018 | 2018-08-06 | A |
| ROP | Roper Technologies, Inc. | Q2 2018 | 2018-07-26 | A |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
SYM · Q3 2022 → YESThe question is: Does management describe that the people on the OTHER SIDE of the company's business are now PUTTING THEIR OWN MONEY OR RESOURCES AT RISK BEFORE they receive what they are paying for ...YES The transcript shows management describing real advance commitments from customers: the $11.3 billion backlog (more than doubled), strong deferred revenue on the balance sheet representing a "very significant cost float," and contracts that lock in commitments with restricted changes. Revenue is recognized on a percentage-of-completion basis during deployment, meaning payments 18 months ahead of acceptance. This is framed as an active benefit enabling confident scaling, not a routine or historical norm. They also note improved supplier terms, but the customer-side pre-funding via deferred revenue and backlog is explicitly highlighted as occurring now. This meets the criteria for counterparties committing capital ahead of delivery.
EVGO · Q2 2022 → YESThe question is: Does management describe that the people on the OTHER SIDE of the company's business are now PUTTING THEIR OWN MONEY OR RESOURCES AT RISK BEFORE they receive what they are paying for ...YES The transcript shows management describing the eXtend model with Pilot and GM where the customer (Pilot/GM) incurs the upfront capital expenditures for the charging infrastructure, while EVgo receives ongoing revenues from operations, maintenance, and services. This is presented as an actual, current business arrangement that provides EVgo with immediate cash flow and contracted revenues, not as a future hope or industry norm. Cathy Zoi notes the agreement exceeds IRR hurdles and provides near-term revenue, and Olga Shevorenkova explains the customer funds the build-out, enabling EVgo to generate margin as developer and operator.
BLZE · Q3 2022 → YESThe question is: Does management describe that the people on the OTHER SIDE of the company's business are now PUTTING THEIR OWN MONEY OR RESOURCES AT RISK BEFORE they receive what they are paying for ...YES The transcript shows management describing B2 Reserve as a capacity-based pricing program that includes premium support and free data migration, with revenue ramping in Q3. Frank notes B2 Reserve contracts are "effectively committed contracts," and Gleb calls them "committed contracts" in response to an investor question. This is presented as occurring now, with "initial ramp in demand" and "revenue increasing each month of Q3," not as a future plan or industry norm. The capacity-reservation aspect aligns with the described phenomenon of counterparties committing capital in advance.